Since its founding, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. Operating on a global scale, Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies with approximately 50,000 employees.
- Research and development (R&D) has been the foundation of the company’s success and continues to be the major driver of innovative new medicines that improve the lives of patients and their families. The company concentrates its research efforts and investment in several key scientific focus areas: CardioMetabolic diseases; Central Nervous System diseases; Immunology and Respiratory diseases; and Oncology and Cancer Immunology.
- BI is committed to continuing to make advances in respiratory and cardiovascular health, while also making significant developments in the areas of diabetes and oncology.
- Boehringer Ingelheim recognizes that its competitive advantage is due in part to its commitment to sustaining a culture that encourages diversity in all aspects of the business, whether that be in the diversity of the background of its employees, of the thoughts and ideas, or in the diversity of its partners and suppliers. The Human Rights Campaign recognized BI as one of the Best Places to Work for LGBT Equality from 2012 and 2014-2018.
- BI was named one of the 100 Best Companies by Working Mother in 2010, 2012, and 2014-2018. The company was also ranked a Top 50 Company by the National Association of Female Executives (NAFE) from 2014-2018.
- The Boehringer Ingelheim Cares Foundation is a private nonprofit organization that provides financial contributions to nonprofits that fill unmet needs of patients, families, and communities. The Foundation also provides medicines to patients who need them, both across the U.S. and around the world. The Foundation supports nonprofit programs that improve access to healthcare and enhance Science, Technology, Engineering, and Math (STEM) education with a focus on the underserved. BI has donated $2.7 billion in medicines to patients in the U.S. and around the world since 2001 and $31 million to strengthen communities and address unmet needs.
- 780,000 uninsured and underinsured U.S. patients received free medicines through BI’s Patient Assistance Program.